# EDGAR Filing Document

**Accession Number:** 0001159281
**File Stem:** 0001104659-23-010207
**Filing Date:** 2023-2
**Character Count:** 18529
**Document Hash:** 18d1526ba5827018c6fdac96d44f521a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-010207.hdr.sgml**: 20230203

**ACCESSION NUMBER**: 0001104659-23-010207

**CONFORMED SUBMISSION TYPE**: SC TO-C

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230203

**DATE AS OF CHANGE**: 20230203

**GROUP MEMBERS**: ABP ACQUISITION 2 LLC

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AlerisLife Inc.
- **CENTRAL INDEX KEY:** 0001159281
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-SKILLED NURSING CARE FACILITIES [8051]
- **IRS NUMBER:** 043516029
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-C
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-62369
- **FILM NUMBER:** 23583784

**BUSINESS ADDRESS:**
- **STREET 1:** 400 CENTRE STREET
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02458
- **BUSINESS PHONE:** (617) 796 8387

**MAIL ADDRESS:**
- **STREET 1:** 400 CENTRE STREET
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02458

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FIVE STAR SENIOR LIVING INC.
- **DATE OF NAME CHANGE:** 20170306

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FIVE STAR QUALITY CARE, INC.
- **DATE OF NAME CHANGE:** 20161006

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FIVE STAR QUALITY CARE INC
- **DATE OF NAME CHANGE:** 20010918
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABP Acquisition LLC
- **CENTRAL INDEX KEY:** 0001686016
- **IRS NUMBER:** 813995762
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-C

**BUSINESS ADDRESS:**
- **STREET 1:** TWO NEWTON PLACE
- **STREET 2:** 255 WASHINGTON STREET
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02458
- **BUSINESS PHONE:** 617-796-8390

**MAIL ADDRESS:**
- **STREET 1:** TWO NEWTON PLACE
- **STREET 2:** 255 WASHINGTON STREET
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02458

---

| | |
|:---|:---|
| **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION** | **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION** |
| **Washington, D.C. 20549** | **Washington, D.C. 20549** |
| **SCHEDULE TO** | **SCHEDULE TO** |
| **TENDER OFFER STATEMENT UNDER SECTION 14(D)(1)**<br> **OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934** | **TENDER OFFER STATEMENT UNDER SECTION 14(D)(1)**<br> **OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934** |
| <br> **ALERISLIFE INC.** | <br> **ALERISLIFE INC.** |
| **(Name of Subject Company (Issuer))** | **(Name of Subject Company (Issuer))** |
| **ABP ACQUISITION 2 LLC**<br> **a wholly owned subsidiary of**<br>**ABP ACQUISITION LLC** | **ABP ACQUISITION 2 LLC**<br> **a wholly owned subsidiary of**<br>**ABP ACQUISITION LLC** |
| **(Names of Filing Persons (Offeror))** | **(Names of Filing Persons (Offeror))** |
| **Common Stock, Par Value $0.01 Per Share** | **Common Stock, Par Value $0.01 Per Share** |
| **(Title of Class of Securities)** | **(Title of Class of Securities)** |
| **33832D205** | **33832D205** |
| **(Cusip Number of Class of Securities)** | **(Cusip Number of Class of Securities)** |
| **Adam D. Portnoy**<br> **President**<br> **ABP Acquisition LLC**<br> **255 Washington Street**<br> **Newton, MA 02458**<br> **(617) 928-1300** | **Adam D. Portnoy**<br> **President**<br> **ABP Acquisition LLC**<br> **255 Washington Street**<br> **Newton, MA 02458**<br> **(617) 928-1300** |
| **(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)** | **(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)** |
| <br> **With copies to:** | <br> **With copies to:** |
| <br> **Faiz Ahmad**<br> **Skadden, Arps, Slate, Meagher & Flom LLP**<br> **920 North King Street<br> Wilmington, DE 19801**<br> **(302) 651-3250** | <br> **Faiz Ahmad**<br> **Skadden, Arps, Slate, Meagher & Flom LLP**<br> **920 North King Street<br> Wilmington, DE 19801**<br> **(302) 651-3250** |
| **CALCULATION OF FILING FEE** | **CALCULATION OF FILING FEE** |
| **Transaction Valuation\*** | **Amount of Filing Fee\*** |
| N/A | N/A |
| <br> \* A filing fee is not required in connection with this filing as it relates solely to preliminary communications made before the commencement of the tender offer. | <br> \* A filing fee is not required in connection with this filing as it relates solely to preliminary communications made before the commencement of the tender offer. |
| <br> ◻ Check box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | <br> ◻ Check box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
| Amount Previously Paid: | &nbsp;&nbsp;&nbsp; Not applicable |
| Form or Registration No.: | &nbsp;&nbsp;&nbsp; Not applicable |

---

⌧ Check
the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

⌧ third-party tender offer subject to Rule 14d-1.<br> ◻ issuer tender offer subject to Rule 13e-4.<br> ⌧ going-private transaction subject to Rule 13e-3.<br> ◻ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer. ◻

This filing relates solely to preliminary communications made before the commencement of a tender offer by ABP Acquisition 2 LLC, a Maryland limited liability company ("Purchaser"), and a wholly owned subsidiary of ABP Acquisition LLC, a Maryland limited liability company ("ABP Acquisition"), to acquire all of the outstanding shares of common stock of AlerisLife, Inc., a Maryland corporation (the "Company") (other than Shares held by Parent, Purchaser, any other direct or indirect wholly owned subsidiary of Parent or any person that owns, directly or indirectly, all of the outstanding equity interests of Purchaser), at a price of $1.31 per Share, net to the seller in cash, without interest and subject to any withholding of taxes pursuant to an Agreement and Plan of Merger, dated February 2, 2023, among the Company, ABP Acquisition and Purchaser.

**Notice to Investors and Security Holders**

The tender offer referred to in this filing and related exhibits has not yet commenced. The description contained in this filing and related exhibits is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Purchaser will file with the Securities and Exchange Commission (the "SEC"). The solicitation and offer to buy shares of the Company's common stock will only be made pursuant to an offer to purchase and related tender offer materials. At the time the tender offer is commenced, Purchaser will file a tender offer statement on Schedule TO and thereafter the Company will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the Offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. THE COMPANY'S SHAREHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. The offer to purchase, the related letter of transmittal and the solicitation/recommendation statement will be made available free of charge at the SEC's website at www.sec.gov. Additional copies may be obtained for free by contacting ABP Acquisition or the Company. Copies of the documents filed with the SEC by the Company will be available free of charge on the Company's internet website at https:/alerislife.com/ or by contacting the Issuer's investor relations contact at (617) 796-8245.

In addition to the offer to purchase, the related letter of transmittal and certain other tender offer documents to be filed by Purchaser, as well as the solicitation/recommendation statement to be filed by the Company, the Company will also file annual, quarterly, and current reports with the SEC as required prior to the Closing (as defined in the Merger Agreement) and for a limited period thereafter as may be required. The Company's filings with the SEC are available to the public from commercial document-retrieval services and at the website maintained by the SEC at http://www.sec.gov.

**Forward-Looking Statements**

ABP Acquisition and the Company assume no obligation to update forward-looking statements contained in this filing and related exhibits as a result of new information or future events or developments except as required by law. This filing and related exhibits include forward-looking statements regarding the business of the Company and ABP Acquisition and the proposed acquisition of the Company that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Any statement describing the Company's or ABP Acquisition's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties. Risks and uncertainties also include, among other things, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition in the anticipated timeframe or at all, including uncertainties as to how many of the Company's stockholders will tender their Shares in the tender offer and the possibility that the acquisition does not close; disruption from the transaction making it more difficult to maintain business and operational relationships; and the magnitude of transaction costs. The Company's and ABP Acquisition's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although the Company's and ABP Acquisition's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company and ABP Acquisition. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning the Company's programs are described in additional detail in the Company's quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the SEC. Copies of these and other documents are available from the Company.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| [99.1](tm235316d2_ex99-1.htm) | [Press Release, issued by the Company on February 3, 2023.](tm235316d2_ex99-1.htm) |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| ![](tm235316d2_ex99-1img003.jpg) | ![](tm235316d2_ex99-1img002.jpg) |

---

**<u>FOR IMMEDIATE RELEASE</u>**

**ABP Acquisition to Acquire AlerisLife for $1.31 Per Share**

*Purchase Price Provides Shareholders with an 85% Premium to Average Share Price of Last 30 Trading Days*

**<u>Newton,MA</u>** (February **3**, 2023): <u>AlerisLife Inc. (Nasdaq: ALR)</u> today announced that it has entered into a definitive agreement with ABP Acquisition LLC, or ABP, under which ABP will acquire all of the outstanding shares of ALR common stock for $1.31 per share in cash, which represents an 85% premium to the average trading price of the last 30 trading days of $0.71 per share. The total consideration to be paid to stockholders in the transaction is approximately $43.8 million and is not subject to any financing condition. ABP is majority owned and controlled by Adam Portnoy, one of ALR's managing directors and the chair of its Board of Directors.

ABP plans to acquire ALR through a tender offer which will be subject to, among other things, a number of shares being tendered in the tender offer that, together with the shares owned by ABP and its affiliates, represent a majority of ALR shares. ABP together with its affiliates currently own approximately 6.1% of ALR's outstanding shares of common stock. Diversified Healthcare Trust (Nasdaq: DHC), which holds approximately 31.9% of the outstanding shares of ALR common stock, has also consented to the transaction and has agreed to tender its shares in the tender offer. Promptly following completion of the tender offer, ABP will acquire all remaining shares of ALR at the same price of $1.31 per share in cash through a merger. The tender offer is expected to launch promptly, and the Board will recommend that shareholders tender their shares. The transaction is expected to be completed in the first quarter of 2023.

The transaction was unanimously recommended by a special committee of the ALR Board of Directors comprised entirely of independent directors and approved by the ALR Board of Directors. The special committee engaged Citigroup Global Markets Inc. as its financial advisor in connection with the transaction.

![](tm235316d2_ex99-1img004.jpg)

---

| | |
|:---|:---|
| ![](tm235316d2_ex99-1img003.jpg) | ![](tm235316d2_ex99-1img002.jpg) |

---

**About AlerisLife (Nasdaq: ALR):**

AlerisLife enriches and inspires the lives of its older adult customers across the United States by delivering an exceptional and enhanced resident experience to senior living and active adult residents, while also offering lifestyle services to the younger "choice-based" consumer. The Company is headquartered in Newton, Massachusetts. For more information, visit <u>www.alerislife.com</u>.

**Additional Information and Where to Find It**

The tender offer referred to in this communication has not yet commenced. The description contained in this communication is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that ABP will file with the Securities and Exchange Commission (the "SEC"). The solicitation and offer to buy shares of ALR common stock will only be made pursuant to an offer to purchase and related tender offer materials. Upon commencement of the tender offer, ABP will file with the SEC a Tender Offer Statement on Schedule TO and a Transaction Statement on Schedule 13E-3 ("Schedule 13E-3"). Following commencement of the Offer, ALR will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 ("Schedule 14D-9"). Holders of shares of ALR common stock are urged to read the Tender Offer Statement (including the offer to purchase, a related letter of transmittal and other offer documents filed with the SEC), the Schedule 13E-3 and the Schedule 14D-9 when such documents become available, as they will contain important information about the tender offer. Holders of ALR common stock can obtain these documents when they are filed and become available free of charge from the SEC's website at www.sec.gov, or from ALR upon written request to AlerisLife Inc., Two Newton Place, 255 Washington Street, Suite 230, Newton, MA 02458, telephone number (617) 796-8387 or from ALR's website, www.alerislife.com.

![](tm235316d2_ex99-1img004.jpg)

---

| | |
|:---|:---|
| ![](tm235316d2_ex99-1img003.jpg) | ![](tm235316d2_ex99-1img002.jpg) |

---

**Cautionary Statement Regarding Forward-Looking Statements**

This communication includes forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of ALR and members of its senior management team and can typically be identified by words such as "believe," "expect," "estimate," "predict," "target," "potential," "likely," "continue," "ongoing," "could," "should," "intend," "may," "might," "plan," "seek," "anticipate," "project" and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the tender offer for ALR (the "Offer") and the second-step merger with ALR, with ALR continuing as the surviving corporation (the "Merger"); and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: the possibility that various closing conditions for the Offer or the Merger may not be satisfied or waived the effects of the Offer or the Merger (or the announcement thereof) on relationships with customers, vendors, other business providers and relations or governmental entities; the risk that the Merger will divert management's attention from ALR's ongoing business operations; changes in ALR's businesses during the period between now and the Offer Acceptance Time; risks associated with litigation; and other risks and uncertainties , including those noted from time to time in documents filed with the SEC by ALR, including Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K, as well as the Schedule 14D-9 to be filed by ALR. All forward-looking statements are based on information currently available to ALR, and ALR assumes no obligation to update any forward-looking statements, except as required by law.

Contact: <br> Melissa McCarthy, Manager, Investor Relations<br> (617) 796-8245

(end)

![](tm235316d2_ex99-1img004.jpg)